title: Serotyping and multilocus sequence typing of Streptococcus pneumoniae isolates from the blood and posterior nares of Japanese children prior to the introduction of 7-valent pneumococcal conjugate vaccine.
abstract: In Japan, the 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in 2010. To assess the effects of PCV7 on invasive pneumococcal infection in children, a population-based prospective survey has been conducted in 10 prefectures. As a part of the study, blood and nasopharyngeal isolates from children admitted to the Shibata Hospital, Niigata Prefecture, were analyzed for determining the serotypes, their susceptibilities to antimicrobial agents, and multilocus sequence types. Sixteen blood isolates were obtained from October 2007 to December 2009. Sixty-three nasopharyngeal isolates were obtained from the posterior nares of 118 children with pneumonia from April to September 2008. The coverage rates of the blood and nasopharyngeal isolates for PCV7 were 81.3% and 57.1%, respectively. Although none of these children had received PCV7, serotype 19A isolates were recovered from 12.5% (2/16) of the blood samples and 12.7% (8/63) of the nasopharyngeal samples. The sequence type of a nasopharyngeal isolate of serotype 19A was ST320, and the minimum inhibitory concentration of penicillin G was 4 μg/mL. In addition to the continuous prospective survey of pneumococcal infection, early introduction of the 13-valent conjugate vaccine, in which the 19A conjugate is included, will be necessary in Japan.
authors.affiliation: Department of Pediatrics, Niigata University Medical and Dental Hospital, Niigata 951-8520, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Oishi
authors.forename: Akihito
authors.initials: A
authors.lastname: Wada
authors.forename: Bin
authors.initials: B
authors.lastname: Chang
authors.forename: Shinichi
authors.initials: S
authors.lastname: Toyabe
authors.forename: Makoto
authors.initials: M
authors.lastname: Uchiyama
mesh_terms: D000293:Adolescent; D016470:Bacteremia / Q000382:microbiology; D001769:Blood / Q000382:microbiology*; D002648:Child; D002675:Child, Preschool; D024881:Drug Resistance, Bacterial; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006776:Hospitals, Pediatric; D006801:Humans; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008826:Microbial Sensitivity Tests; D058885:Multilocus Sequence Typing; D009305:Nasopharynx / Q000382:microbiology*; D010400:Penicillin G / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D011018:Pneumonia, Pneumococcal / Q000453:epidemiology / Q000382:microbiology; D011446:Prospective Studies; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines; D010400:Penicillin G